What one share of ProQR Therapeutics holds
We are a clinical-stage biotechnology company advancing a pipeline (Figure 1) of RNA editing therapeutics based on our proprietary Axiomer RNA-editing platform. Our lead program, AX-0810 for cholestatic diseases targeting na-taurocholate cotransporting polypeptide (“NTCP”), is currently being evaluated in a Phase 1 clinical trial in healthy volunteers.
ProQR Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.17 |
|---|---|
| Profit | −$0.45 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.58 |
| Cash and investments | $1.03 |
| Debt | $0.05 |
| Book value | $0.55 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$0.99 | $0.06 | −$1.21 | — | $4.18 |
| 2016 | — | −$1.85 | $0.12 | −$1.74 | — | $2.40 |
| 2017 | — | −$1.94 | $0.01 | −$1.56 | — | $1.48 |
| 2018 | — | −$1.28 | $0.01 | −$1.00 | — | $2.74 |
| 2019 | — | −$1.54 | $0.02 | −$1.22 | — | $2.13 |
| 2020 | — | −$1.06 | $0.02 | −$1.09 | — | $1.29 |
| 2021 | $0.02 | −$1.12 | $0.01 | −$0.49 | — | $1.81 |
| 2022 | $0.05 | −$0.95 | $0.01 | −$1.02 | — | $0.89 |
| 2023 | $0.09 | −$0.38 | $0.02 | $0.27 | — | $0.56 |
| 2024 | $0.24 | −$0.35 | $0.02 | −$0.48 | — | $0.87 |
| 2025 | $0.17 | −$0.45 | $0.01 | −$0.58 | — | $0.55 |
Common questions about ProQR Therapeutics
How much does one share of ProQR Therapeutics earn?
Over its latest fiscal year, ProQR Therapeutics lost $0.45 for each share on $0.17 of sales.
Does ProQR Therapeutics pay a dividend?
ProQR Therapeutics didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is ProQR Therapeutics’s book value per share?
ProQR Therapeutics’s book value is $0.55 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of ProQR Therapeutics have?
Each share of ProQR Therapeutics has $1.03 of cash and investments and $0.05 of debt, as of December 31, 2025.
What is ProQR Therapeutics’s free cash flow per share?
−$0.58 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has ProQR Therapeutics bought back shares?
ProQR Therapeutics’s share count rose about 351% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.